First-line Treatment Selection for Advanced Hepatocellular Carcinoma

Authors

  • Zainab Al Maqrashi, MD, MSc McMaster University, Hamilton, Ontario, Canada
  • Brandon M. Meyers, MD, MSc, FRCPC Juravinski Cancer Centre, Hamilton, Ontario, Canada, McMaster University, Department of Oncology, Hamilton, Ontario, Canada, Escarpment Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada

DOI:

https://doi.org/10.58931/cot.2024.1325

Abstract

The treatment landscape of advanced/unresectable hepatocellular carcinoma (uHCC) has rapidly evolved since 2018. Over recent years, various systemic therapies and treatment approaches have been explored. Systemic therapy has primarily relied on tyrosine kinase inhibitors (TKIs); however, immune checkpoint inhibitors (ICIs) have more recently entered the realm of the treatment armamentarium.

Author Biographies

Zainab Al Maqrashi, MD, MSc, McMaster University, Hamilton, Ontario, Canada

Dr. Zainab is a medical oncology resident at McMaster University. She joined McMaster University from Oman in 2020 where she completed her internal medicine training. Her professional areas of interest and focus include gastrointestinal neoplasm research, and medical education. 

Brandon M. Meyers, MD, MSc, FRCPC, Juravinski Cancer Centre, Hamilton, Ontario, Canada, McMaster University, Department of Oncology, Hamilton, Ontario, Canada, Escarpment Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada

Dr. Meyers is an Associate Professor/Attending Medical Oncologist at the Juravinski Cancer Centre, McMaster University. His clinical practice primarily focusses on Gastrointestinal – liver, colorectal, and pancreas, and Head and Neck malignancies. He is a co-chair of the CMHCC conference, and co-lead on a number of liver initiated projects within Cancer Care Ontario.

References

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine. 2008;359(4):378-90.

Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet. 2018;391(10126):1163-73.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-905.

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862-73.

Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Journal of Clinical Oncology. 2022;40(4_suppl):379-.

Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024.

Galle PR, Decaens T, Kudo M, Qin S, Fonseca L, Sangro B, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. Journal of Clinical Oncology. 2024;42(17_suppl):LBA4008-LBA.

Breder VV, Vogel A, Merle P, Finn RS, Galle PR, Zhu AX, et al. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. Journal of Clinical Oncology. 2021;39(15_suppl):4073-.

Ha Y, Kim JH, Cheon J, Jeon GS, Kim C, Chon HJ. Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab. Clin Gastroenterol Hepatol. 2023;21(9):2421-3.e2.

Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991-1001.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66.

Abou-Alfa GK, Meyer T, Cheng A-L, El-Khoueiry AB, Rimassa L, Ryoo B-Y, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine. 2018;379(1):54-63.

Hepatocellular Carcinoma: NCCN Clinical Practice Guidelines in Oncology; 2023 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf.

Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023;8(3):101567.

Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38(36):4317-45.

Meyers BM, Knox J, Cosby R, Beecroft JR, Chan KKW, Coburn N, et al. Nonsurgical Management of Advanced Hepatocellular Carcinoma: A Clinical Practice Guideline. Current Oncology. 2020;27(2):106-14.

Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. Journal of Hepatology. 2019;71(6):1164-74.

Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). Journal of Clinical Oncology. 2023;41(1):117-27.

Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, et al. NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 2023;41(4_suppl):489-.

Lencioni R, Kudo M, Erinjeri J, Qin S, Ren Z, Chan S, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Journal of Clinical Oncology. 2024;42(3_suppl):LBA432-LBA.

Downloads

Published

2024-10-28

How to Cite

Al Maqrashi, Z., & Meyers, B. M. (2024). First-line Treatment Selection for Advanced Hepatocellular Carcinoma. Canadian Oncology Today, 1(3), 4–9. https://doi.org/10.58931/cot.2024.1325

Issue

Volume 1, Issue 3, Fall 2024

Section

Articles

License

Copyright (c) 2024 Canadian Oncology Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.